Cortexyme

Bluebird suspends gene therapy trials after two sickle cell patients develop cancer Bluebird bio has stopped two clinical trials of its sickle cell disease gene therapy after participants developed acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). During the pause, bluebird will assess whether the ...

Alzheimer's Disease Market finally witnessed the approval of standard therapy, Aducanumab, by Biogen. What impact does it hold for the future? Demographic or population ageing is a global and dominant phenomenon of the 21st century. Different geographies are experiencing population ageing at different rates. As ...

The ageing population is a global phenomenon. According to the UN’s “World Population Prospects 2019” by 2100, the world’s population is projected to reach approximately 10.9 billion. Moreover, between 2020 and 2100, the number of people ages 80 and older is expected to increase from 146 million to 881 million. ...